17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial - 19/08/11
Résumé |
Objective |
We sought to determine whether prophylactic treatment with 17-alpha-hydroxyprogesterone caproate (17Pc) in twin pregnancy will reduce neonatal morbidity (primary outcome) by prolonging pregnancy (secondary outcome).
Study Design |
This was a double-blind, randomized clinical trial. Mothers carrying dichorionic-diamniotic twins were randomly assigned (in a 2:1 ratio) to weekly injections of 250 mg of 17Pc or placebo, starting at 16-24 weeks and continued until 34 weeks.
Results |
In all, 160 women were randomized to 17Pc and 80 to placebo. Composite neonatal morbidity occurred with similar frequency in the 17Pc and placebo groups (14% vs 12%, respectively, P = .62). Mean gestational age at delivery was not affected by 17Pc (35.3 vs 35.9 weeks, P = .10), but a 3-day difference in median gestational age favored placebo (P = .02). There were no perinatal deaths with 17Pc and 3 with placebo.
Conclusion |
In twin pregnancy, prophylactic treatment with 17Pc did not prolong gestation or reduce neonatal morbidity.
Le texte complet de cet article est disponible en PDF.Key words : 17-hydroxyprogesterone, preterm delivery, progesterone, twins
Plan
| Supported by a grant from the Center for Research, Education, and Quality, Pediatrix Medical Group, Mednax Inc, Sunrise, FL. |
|
| The racing flag logo above indicates that this article was rushed to press for the benefit of the scientific community. |
|
| Reprints not available from the authors. |
|
| Cite this article as: Combs CA, Garite T, Maurel K, et al. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 2011;204:221.e1-8. |
Vol 204 - N° 3
P. 221.e1-221.e8 - mars 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
